Hermab 150 mg injection | Trastuzumab |Blueberry pharmaceuticals

Hermab 150mg is a type of drugs which belongs to anticancer medication. Hermab 150mg injection consist of a targeted cancer drug known as Transtuzumab, which is pharmacologically classified as humanized monoclonal antibody produced by recombinant DNA technology. Hermab 150mg is a prescription drug and to be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

INJECTION PRESCRIBED FOR
The injection Hermab 150mg is indicated alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also used with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

Brand  : Hermab
Ingredients : Trastuzumab
Strength : 150mg
Manufactured : RPG life Sciences Ltd

COMMON SIDE EFFECTS
Redness at injection site (IV) Muscle/joint/back pain Insomnia Tiredness Mild skin rash Stuffy nose Sinus pain

SERIOUS SIDE EFFECTS
Increased coughing Sudden unexplained weight gain Unusual tiredness Easy bruising or bleeding Fast or pounding heartbeat Increased coughing

DOSAGE AND ADMINISTRATION
The Hermab 150mg injection should not combine with other drugs and do not administer as an intravenous push or bolus. Trastuzumab should not be give alternative for or with ado-Trastuzumab emtansine Adjuvant treatment, breast cancer:
The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:

DURING COMBINATION WITH PACLITAXEL, DOCETAXEL, OR DOCETAXEL /CARBOPLATIN
Initiating dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin)
The Hermab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.
The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.

METASTATIC TREATMENT, BREAST CANCER
Hermab 150mg given treatment alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.

METASTATIC GASTRIC CANCER
Hermab 150mg administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

CONTRAINDICATIONS
No Possibility of contraindicated occurs. The patients are contraindicated to the component present in the Hermab 150mg, Hence Hypersensitivity reactions are occurring.